12:00 AM
Aug 18, 2014
 |  BC Week In Review  |  Clinical News  |  Regulatory

AB103 regulatory update

Atox Bio said the European Commission granted Orphan Drug designation to AB103 to treat necrotizing soft tissue infections. The...

Read the full 72 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >